Results 11 to 20 of about 4,522 (127)

4β-Hydroxycholesterol Signals From the Liver to Regulate Peripheral Cholesterol Transporters [PDF]

Frontiers in Pharmacology, 2020
Activation of pregnane X receptor (PXR) elevates circulating 4β-hydroxycholesterol (4βHC), an agonist of liver X receptor (LXR). PXR may also regulate 25-hydroxycholesterol and 27-hydroxycholesterol.
Tuire Salonurmi, Tuire Salonurmi, Heba Nabil, Heba Nabil, Heba Nabil, Justiina Ronkainen, Justiina Ronkainen, Tuulia Hyötyläinen, Heidi Hautajärvi, Markku J. Savolainen, Markku J. Savolainen, Markku J. Savolainen, Ari Tolonen, Matej Orešič, Päivi Känsäkoski, Jaana Rysä, Jukka Hakkola, Jukka Hakkola, Jukka Hakkola, Janne Hukkanen, Janne Hukkanen, Janne Hukkanen   +21 more
doaj   +4 more sources

Role of oxysterol 4β-hydroxycholesterol and liver X receptor alleles in pre-eclampsia [PDF]

Annals of Medicine
Background Liver X receptors (LXRs) are expressed in placenta and may be associated with pre-eclampsia (PE). Oxysterols act as agonists for LXRs. We recently proposed a new blood pressure-regulating circuit with oxysterol 4β-hydroxycholesterol (4βHC ...
Lassi Kaartinen, Tiina Jääskeläinen, Eeva Sliz, Gamze Yazgeldi Gunaydin, Satu Wedenoja, Shintaro Katayama, Eero Kajantie, Valtteri Rinne, Seppo Heinonen, Juha Kere, Heta Merikallio, Eeva Sliz, Hannele Laivuori, Janne Hukkanen   +13 more
doaj   +5 more sources

No impact of vitamin D on the CYP3A biomarker 4β-hydroxycholesterol in patients with abnormal glucose regulation. [PDF]

PLoS ONE, 2015
PURPOSE:To investigate the effect of vitamin D3 on hepatic Cytochrome P450 enzyme (CYP) 3A4 in patients with abnormal glucose regulation using the endogenous marker 4β-hydroxycholesterol (4β-OHC):cholesterol ratio.
Buster Mannheimer, Henrik Wagner, Claes-Göran Östenson, Ulf Diczfalusy   +3 more
doaj   +3 more sources

Liver X Receptor Agonist 4β‐Hydroxycholesterol as a Prognostic Factor in Coronary Artery Disease [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Regardless of progress in treatment of coronary artery disease (CAD), there is still a significant residual risk of death in patients with CAD, highlighting the need for additional risk stratification markers.
Roosa Rahunen, Mikko Tulppo, Valtteri Rinne, Samuli Lepojärvi, Juha S. Perkiömäki, Heikki V. Huikuri, Olavi Ukkola, Juhani Junttila, Janne Hukkanen   +8 more
doaj   +4 more sources

Drug–Drug Interaction Risk Assessment Strategies for Biologics in Inflammatory Bowel Disease: A Literature‐Based Evidence Mini‐Review [PDF]

Clinical and Translational Science
Biologic therapies are traditionally regarded as having low potential for drug–drug interactions (DDIs) due to their large molecular size and limited direct involvement with drug‐metabolizing enzymes and transporters (DMETs).
Claire Steinbronn, Susan E. Stanley, Tjerk Bueters, Sihem Ait‐Oudhia   +3 more
doaj   +3 more sources

Significant increase in plasma 4β-hydroxycholesterol concentration in patients after kidney transplantation [PDF]

Journal of Lipid Research, 2013
Several previous studies have shown that renal failure decreases not only renal elimination but also metabolic clearance of drugs, particularly those metabolized by CYP3A.
Yosuke Suzuki, Hiroki Itoh, Fuminori Sato, Kanako Kawasaki, Yukie Sato, Takashi Fujioka, Yuhki Sato, Keiko Ohno, Hiromitsu Mimata, Satoshi Kishino   +9 more
doaj   +2 more sources

Correction: Taya et al. Clinical Evaluation Based on a New Approach to Improve the Accuracy of 4β-Hydroxycholesterol Measurement as a Biomarker of CYP3A4 Activity. Molecules 2023, 28, 1576 [PDF]

Molecules
In the original publication [...]
Yuki Taya, Mari Mizunaga, Shunsuke Nakao, Mirinthorn Jutanom, Naoki Shimizu, Yukihiro Nomura, Kiyotaka Nakagawa   +6 more
doaj   +2 more sources

Serum 4β-hydroxycholesterol increases during fluconazole treatment. [PDF]

Eur J Clin Pharmacol, 2021
Purpose: The antifungal drugs ketoconazole and itraconazole reduce serum concentrations of 4β-hydroxycholesterol, which is a validated marker for hepatic cytochrome P450 (CYP) 3A4 activity.
Lütjohann D, Stellaard F, Kerksiek A, Lötsch J, Oertel BG.   +4 more
europepmc   +2 more sources

Estrogen associations with human pregnancy related increases in cytochrome P450 3A activity [PDF]

Frontiers in Pharmacology
IntroductionIncreased CYP3A-mediated drug clearance during pregnancy can lead to subtherapeutic dosing of CYP3A substrates. Pregnancy-related hormones (PRHs) increase CYP3A4 expression and activity in cultured human hepatocytes.
Muluneh M. Fashe, Jonghwa Lee, Joseph T. Grieco, John K. Fallon, Ian R. Mulrenin, Megan N. Gower, Klarissa D. Jackson, Kim A. Boggess, Craig R. Lee   +8 more
doaj   +2 more sources

Dynamic phenotype monitoring to prevent genotype–phenotype discrepancies in pharmacogenetic-guided drug therapy [PDF]

Frontiers in Pharmacology
BackgroundOne of the limiting factors for the clinical application of pharmacogenomics (PGx) is phenoconversion, i.e., the dynamic discrepancy between genotype-predicted and actual drug-metabolizing phenotypes.
Pálma Porrogi
doaj   +2 more sources